Shares of IVD Medical Holding surged by 8.6% to HK$11.53, marking the company’s largest one-day percentage increase since early September. This rise comes following the announcement of a strategic partnership with biopharma developer Transcenta Holding. The collaboration aims to explore the application of Real-World Asset Tokens on the Ethereum blockchain, which positions both companies at the forefront of a novel financing strategy in biotech.
The partnership will focus on funding the preclinical and clinical development of oncology treatments using what the companies describe as a “first-of-its-kind” approach. While specific details regarding the amount of funds to be raised were not disclosed, both firms indicated that their consolidated assets boast a substantial combined valuation exceeding $1.5 billion.
Transcenta shares also experienced a notable increase, rising 6.4% to HK$4.85, which is its highest level since mid-September. Year to date, IVD shares have skyrocketed nearly 504%, while Transcenta has seen an impressive rise of 594%. In contrast, the Hang Seng Biotech Index has increased by 99% over the same period, highlighting the significant outperformance of these two companies in the biotech sector.
